GlassScriptPhysician profile
Tina Cascone
NPI 1922353135
$193,637.50
in general payments reported to CMS, 2019-2025
15 companies · $32K in 2025
The $32K reported for 2025 was more than what 92% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $11K · 2021: $13K · 2022: $11K · 2023: $63K · 2024: $49K · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $113K · Travel and Lodging: $21K · Education: $5,410 · Food and Beverage: $3,684 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $113,006.25 |
| Travel and Lodging | $20,685.42 |
| Education | $5,410.00 |
| Food and Beverage | $3,683.73 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,440.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $62,900.50 | 2019-2025 | Opdivo |
| Astrazeneca Uk Limited | $45,362.82 | 2023-2025 | Tagrisso |
| Merck Sharp & Dohme LLC | $33,642.29 | 2019-2025 | Keytruda |
| Astrazeneca Pharmaceuticals LP | $20,954.76 | 2019-2025 | Tagrisso, Datroway, Imfinzi |
| Emd Serono, INC. | $10,852.66 | 2019 | |
| Pfizer INC. | $9,998.68 | 2023-2025 | |
| Daiichi Sankyo INC. | $2,177.45 | 2023-2024 | Enhertu |
| Regeneron Pharmaceuticals, INC. | $2,164.68 | 2022 | |
| Janssen Biotech, INC. | $2,045.89 | 2025 | Rybrevant |
| Genentech USA, INC. | $1,667.78 | 2023-2025 | Tecentriq, Alecensa |
| Genentech, INC. | $1,650.00 | 2021 | |
| Jazz Pharmaceuticals INC. | $181.05 | 2024-2025 | |
| Amgen INC. | $24.73 | 2021 | |
| Astrazeneca Ab | $14.21 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tina Cascone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.